Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma

Pediatr Blood Cancer. 2014 Apr;61(4):612-7. doi: 10.1002/pbc.24790. Epub 2013 Sep 30.

Abstract

Background: Osteosarcoma (OS) is the most common childhood bone cancer. Chemoresistance is the principal reason for poor survival and disease recurrence in OS patients, and ET-1 reportedly plays an important role in the development of chemoresistance in OS cells. In the present study, we for the first time explored the association of endothelin-1 (ET-1) SNPs and haplotypes with the risk of chemoresistant pediatric OS.

Procedure: We genotyped three SNPs (rs1800541, rs2070699, and rs5370) in the ET-1 gene in a case-control study, using 350 pairs of age, sex, and tumor location and stage matched pediatric patients with OS. Patients who showed <90% tumor necrosis after neochemotherapy were defined as poor responders (cases), and those who showed ≥90% tumor necrosis were defined as good responders (controls).

Results: The G allele at rs1800541 and the G allele at rs2070699 were associated with reduced and increased risk of chemoresistant OS, respectively. The rs1800541-rs2070699 haplotypes TG and GT were respectively associated with increased (P = 0.012; adjusted OR, 1.82; 95% CI, 1.10-5.65) and reduced (P = 0.009; adjusted OR, 0.25; 95% CI, 0.14-0.84) risk of chemoresistant OS. The TG and the GT haplotypes have a gene-dosage effect on increasing and decreasing the ET-1 expression in primary OS tumor cells from chemoresistant pediatric OS subjects, respectively.

Conclusions: This study provides the first evidence of an association between the ET-1 gene SNPs and haplotypes and the risk of chemoresistant pediatric OS, potentially adding new insights into the pathophysiology and treatment of chemoresistant OS.

Keywords: chemoresistance; endothelin-1; haplotype; osteosarcoma; single nucleotide polymorphism.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / etiology*
  • Bone Neoplasms / pathology
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Drug Resistance, Neoplasm / genetics*
  • Endothelin-1 / genetics*
  • Female
  • Follow-Up Studies
  • Genotype
  • Haplotypes / genetics*
  • Humans
  • Male
  • Neoplasm Staging
  • Osteosarcoma / drug therapy
  • Osteosarcoma / etiology*
  • Osteosarcoma / pathology
  • Polymerase Chain Reaction
  • Polymorphism, Single Nucleotide / genetics*
  • Prognosis

Substances

  • Endothelin-1